As of June 30, 2026, Annovis Bio, Inc. carries a market capitalization of 79.25M, placing it among publicly traded companies globally. Its enterprise value stands at 60.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 79.25M |
| Enterprise Value | 60.52M |
Annovis Bio, Inc.'s next confirmed earnings release is scheduled for April 6, 2027.
| Earnings Date | 4/6/2027 |
As of June 30, 2026, Annovis Bio, Inc. has 42.61M shares outstanding.
| Shares Outstanding | 42.61M |
These figures are as of June 30, 2026.
| PB Ratio | -18.63 |
| P/TBV Ratio | -18.63 |
| P/FCF Ratio | -1.18 |
| P/OCF Ratio | -1.18 |
As of June 30, 2026, Annovis Bio, Inc. maintains a current ratio of 3.47, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.47 |
| Quick Ratio | 2.95 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -227.74, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -227.74 |
| Employee Count | 8.00 |
As of the close on November 16, 2026, Annovis Bio, Inc.'s stock has declined approximately 67.95% over the past 52 weeks. The 50-day moving average sits at 1.09, while the 200-day moving average is 1.80.
| 52-Week Price Change | -67.95% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.80 |
Over the twelve months ended June 30, 2026, Annovis Bio, Inc. generated - - in revenue and converted that into -49.52M in net income, yielding earnings per share of -1.80. EBITDA reached -49.53M, while operating income came in at -49.53M.
| Operating Income | -49.53M |
| Pretax Income | -49.52M |
| Net Income | -49.52M |
| EBITDA | -49.53M |
| EBIT | -49.53M |
| Earnings Per Share (EPS) | -1.80 |
These figures are as of June 30, 2026. Total book value stands at -4.25M, with working capital of 15.68M providing operational flexibility.
| Cash & Cash Equivalents | 18.73M |
| Net Debt | -18.73M |
| Equity (Book Value) | -4.25M |
| Book Value Per Share | -0.10 |
| Working Capital | 15.68M |
Annovis Bio, Inc. produced -43.34M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -43.34M |
| Free Cash Flow | -43.34M |
| FCF Per Share | -1.58 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -84.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -56.71, meaning Annovis Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -56.71 |
| FCF Yield | -84.84 |
As of June 30, 2026, Annovis Bio, Inc. has an Altman Z-Score of -17.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.21 |